Process for T Cell Expansion
AssigneeCell Medica, Inc.
InventorsRainer Ludwig KNAUS, Katy Rebecca NEWTON
Life of this patent
Estimating the term…
Abstract
An in vitro expansion process for rapid expansion of antigen specific T cells, such as allogeneic antigen specific T cells comprising the steps culturing in a gas permeable vessel a population of PBMCs (such as allogeneic PBMCs) in the presence of antigen, for example a peptide or peptide mix relevant to a target antigen(s), in the presence of an exogenous cytokine characterized in that the expansion to provide the desired population of T cells is 14 days or less, for example 9, 10, 11 or 12 days, such as 10 days. The disclosure also extends to T cell populations generated by and obtained from the method and the use of same in therapy.
Claims29
1-34. (canceled)
An in vitro expansion process for rapid expansion of antigen specific T cells, comprising the step of culturing in a vessel comprising a gas permeable culture surface a population of PBMCs in a culture in the presence of an antigen in the form of a peptide or a peptide mix relevant to a target antigen(s) added to the culture in the range of from 1 to 500 ng per ml;
- wherein the culturing is performed in the presence of an exogenous cytokine wherein the cytokine is other than exogenous IL-2 and is selected from the group comprising IL-1, IL-4, IL-6, IL-7, IL-12, IL-15 and combinations thereof;
- and wherein cytokines, media and nutrients are not added or changed after initiation of the expansion process on Day 0;
- and wherein the expansion to provide the desired population of T cells is 14 days or less, wherein the desired population of cells is a CD56− population, and the peptide or peptide mix is/are not added to the culture presented on dendritic cells.
An in vitro process for rapid expansion of antigen specific T cells, comprising the step of culturing in a gas permeable vessel a population of PBMCs in a culture in the presence of an antigen in the form of a peptide or a peptide mix relevant to a target antigen(s) added to the culture in the range of from 1 to 500 ng per ml;
- wherein the culturing is performed in the presence of an exogenous cytokine wherein the cytokine is other than exogenous IL-2 and is selected from the group comprising IL-1, IL-4, IL-6, IL-7, IL-12, IL-15 and combinations thereof;
- wherein the process consists of expanding the antigen-specific T cells for 14, 13, 12, 11, 10, 9, 8, 7 days or less, wherein the desired population of cells is a CD56− population, and the peptide or peptide mix is/are not added to the culture presented on dendritic cells;
- and wherein cytokines, media and nutrients are not added or changed after initiation of the expansion process on Day 0.
Dependencies are inferred from the claim text.